Vipivotide tetraxetan (PSMA-617) is a high-affinity prostate-specific membrane antigen (PSMA) inhibitor (Figure 3) that has recently gained much attention in relation to targeting of prostate cancer metastasis. This evidence concerns the gene FOLH1 and prostate carcinoma.